Angioline company entered the market of the socialist republic of Vietnam
ANGIOLINE Company entered the market of Vietnam. In September, the Company completed the import permit procedure in the Vietnamese regulatory authorities and delivered the first batch of products. The permit was obtained for the COLIBRI balloon catheter and CALIPSO bioresorbable coronary stent, the leaders in Angioline’s range of products.
For the Company, Vietnam is the second foreign market where it is present. Currently, ANGIOLINE delivers its products to the market of Kazakhstan and has plans to start cooperation with medical institutions of Kyrgyzstan. Moreover, in the near future, the completion of product registration in Uzbekistan is expected. Deliveries to the Vietnamese clinics are effected through the single ANGIOLINE’s distributor.
“Death rate from cardiovascular diseases in the Republic of Vietnam is rather high,” says Andrey Kudryashov, Director of ANGIOLINE, LLC, “According to the World Health Organization (WHO), death rate caused by cardiovascular diseases in this country is about 33%, and it is quite a lot. In a situation like this, the authorities are interested in attracting suppliers of high-quality innovative medical products to the market. The procedure for endorsement and obtaining of all the documents required has no extra administrative obstacles and is the most optimized for the foreigners”.